Santen Pharmaceutical Co Ltd 2024 Integrated Report
The report presents Santen's FY2023 record revenue of JPY 302.0 billion and highlights structural reforms that improved profitability. It emphasizes expansion into myopia and ptosis, including development of new treatment options. Sustainability coverage includes TCFD-based climate disclosures, SBTi-approved 2030 targets on a path to net zero by 2050, a biodiversity policy, waste reduction, and human-capital initiatives. It also details the Noto Plant earthquake response and restoration of production lines.
Company: Santen Pharmaceutical Co Ltd
Sector: Manufacturing
Country: Japan
Year: 2024
Type: Integrated Report
Pages: 80
Back to company
Santen Pharmaceutical Co Ltd
Santen Report
The report presents Santen's FY2023 record revenue of JPY 302.0 billion and highlights structural reforms that improved profitability. It emphasizes expansion into myopia and ptosis, including development of new treatment options. Sustainability coverage includes TCFD-based climate disclosures, SBTi-approved 2030 targets on a path to net zero by 2050, a biodiversity policy, waste reduction, and human-capital initiatives. It also details the Noto Plant earthquake response and restoration of production lines.
Sign in for free to access detailed sustainability data, reporting standards, and ESG metrics.
Document Details
Report Year
2024
Reporting Period
Apr 1, 2023 - Mar 31, 2024
Fiscal Year
2023
Type
Integrated Report
Language
English
Pages
File Size
Standards & Assurance
Reporting Standards
Materiality Assessment
ESG Data?Experimental: AI-extracted data, may contain inaccuracies
Energy Consumption
Water Consumption
Women on Board
Women in Management
Net Zero Target
Employees